The Cystic Fibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Cystic Fibrosis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cystic Fibrosis Market.
Some of the key takeaways from the Cystic Fibrosis Pipeline Report:
- Companies across the globe are diligently working toward developing novel Cystic Fibrosis treatment therapies with a considerable amount of success over the years.
- Cystic Fibrosis companies working in the treatment market are Spirovant Sciences, Arcturus Therapeutics, Krystal Biotech, Vertex Pharmaceuticals, AbbVie, Armata Pharmaceutical, Molecular Therapeutics, Eloxx Pharmaceutical, Verona Pharma, Vertex Pharmaceutical, and others, are developing therapies for the Cystic Fibrosis treatment
- Emerging Cystic Fibrosis therapies such as – SP-101, LUNAR CF, KB407, VX-522, Galicaftor/Navoc aftor/ABBV-576, AP-PA02, 4D-710 4D, ELX-02, Ensifentrine, Deutivacaftor/tez acaftor/vanzacaft, and others are expected to have a significant impact on the Cystic Fibrosis market in the coming years.
- In September 2021, In order to assess the effectiveness and safety of VX-121 combination therapy in patients with cystic fibrosis (CF) who are heterozygous for the f508del and a minimal function mutation (F/MF), Vertex Pharmaceuticals started a Phase III, randomised, double-blind, controlled research
- In October 2021, Vertex Pharmaceutical initiated a Phase III, randomised, double-blind, controlledstudy evaluating the efficacy and safety of vx-121 combination therapy in subjects with cystic fibrosis who arehomozygous for f508del, heterozygous for f508del and a gating (f/g) or residual function (f/rf) mutation, or have atleast 1 other triple combination responsive cftr mutation and no f508del mutation
- In May 2021, Vertex Pharmaceuticals Incorporated purchased the potential future milestones related to VX-561 (deutivacaftor) under the firms’ 2017 asset purchase agreement for $32 million, according to an announcement from Concert Pharmaceuticals
Cystic Fibrosis Overview
A mutation in the epithelial chloride channel protein CFTR leads to the genetic condition known as cystic fibrosis (CF), which is a recessive condition. The severity of CF, a hereditary illness that predominates, can range from moderate to life-threatening. Depending on an area’s ethnic makeup, there are different numbers of CF sufferers.
Get a Free Sample PDF Report to know more about Cystic Fibrosis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/cystic-fibrosis-pipeline
Emerging Cystic Fibrosis Drugs Under Different Phases of Clinical Development Include:
- SP-101: Spirovant Sciences
- LUNAR CF: Arcturus Therapeutics
- KB407: Krystal Biotech
- OligoG: Algi Pharma
- MRT5005: Translate Bio
- CB280: Calithera Biosciences
- KB407 : Krystal Biotech
- SPL84231: SpliSense
- VX-522: Vertex Pharmaceuticals
- Galicaftor/Navoc aftor/ABBV-576: AbbVie
- AP-PA02: Armata Pharmaceutical
- 4D-710 4D: Molecular Therapeutics
- ELX-02: Eloxx Pharmaceutical
- Ensifentrine: Verona Pharma
- Deutivacaftor/tez acaftor/vanzacaft: Vertex Pharmaceutical
Route of Administration
Cystic Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
Molecule Type
Products have been categorized under various Molecule types, such as
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
Cystic Fibrosis Pipeline Therapeutics Assessment
- Cystic Fibrosis Assessment by Product Type
- Cystic Fibrosis By Stage and Product Type
- Cystic Fibrosis Assessment by Route of Administration
- Cystic Fibrosis By Stage and Route of Administration
- Cystic Fibrosis Assessment by Molecule Type
- Cystic Fibrosis by Stage and Molecule Type
DelveInsight’s Cystic Fibrosis Report covers around 80+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Cystic Fibrosis product details are provided in the report. Download the Cystic Fibrosis pipeline report to learn more about the emerging Cystic Fibrosis therapies
Some of the key companies in the Cystic Fibrosis Therapeutics Market include:
Key companies developing therapies for Cystic Fibrosis are – Genentech Inc., Novartis AG, Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, AbbVie Inc., GlaxoSmithKline Plc., Johnson & Johnson, Allergan plc, Pharmaxis Ltd., Mylan N.V., Alaxia, Allergan, AstraZeneca, Beyond Air Inc., Hoffmann-La Roche Ltd, Mylan NV, Teva Pharmaceutical Industries Ltd, and others.
Cystic Fibrosis Pipeline Analysis:
The Cystic Fibrosis pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Cystic Fibrosis with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cystic Fibrosis Treatment.
- Cystic Fibrosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Cystic Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cystic Fibrosis market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Cystic Fibrosis drugs and therapies
Cystic Fibrosis Pipeline Market Drivers
- Rising incidence of Cystic Fibrosis, advance research and development over the last few years have contributed to get a clearer picture of the disease, development of the healthcare industry are some of the important factors that are fueling the Cystic Fibrosis Market.
Cystic Fibrosis Pipeline Market Barriers
- However, no standard cure for cystic fibrosis ,adverse effects associated with the drugs and other factors are creating obstacles in the Cystic Fibrosis Market growth.
Scope of Cystic Fibrosis Pipeline Drug Insight
- Coverage: Global
- Key Cystic Fibrosis Companies: Spirovant Sciences, Arcturus Therapeutics, Krystal Biotech, Vertex Pharmaceuticals, AbbVie, Armata Pharmaceutical, Molecular Therapeutics, Eloxx Pharmaceutical, Verona Pharma, Vertex Pharmaceutical, and others
- Key Cystic Fibrosis Therapies: SP-101, LUNAR CF, KB407, VX-522, Galicaftor/Navoc aftor/ABBV-576, AP-PA02, 4D-710 4D, ELX-02, Ensifentrine, Deutivacaftor/tez acaftor/vanzacaft, and others
- Cystic Fibrosis Therapeutic Assessment: Cystic Fibrosis current marketed and Cystic Fibrosis emerging therapies
- Cystic Fibrosis Market Dynamics: Cystic Fibrosis market drivers and Cystic Fibrosis market barriers
Request for Sample PDF Report for Cystic Fibrosis Pipeline Assessment and clinical trials
Table of Contents
|
1 |
Cystic Fibrosis Report Introduction |
|
2 |
Cystic Fibrosis Executive Summary |
|
3 |
Cystic Fibrosis Overview |
|
4 |
Cystic Fibrosis- Analytical Perspective In-depth Commercial Assessment |
|
5 |
Cystic Fibrosis Pipeline Therapeutics |
|
6 |
Cystic Fibrosis Late Stage Products (Phase II/III) |
|
7 |
Cystic Fibrosis Mid Stage Products (Phase II) |
|
8 |
Cystic Fibrosis Early Stage Products (Phase I) |
|
9 |
Cystic Fibrosis Preclinical Stage Products |
|
10 |
Cystic Fibrosis Therapeutics Assessment |
|
11 |
Cystic Fibrosis Inactive Products |
|
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13 |
Cystic Fibrosis Key Companies |
|
14 |
Cystic Fibrosis Key Products |
|
15 |
Cystic Fibrosis Unmet Needs |
|
16 |
Cystic Fibrosis Market Drivers and Barriers |
|
17 |
Cystic Fibrosis Future Perspectives and Conclusion |
|
18 |
Cystic Fibrosis Analyst Views |
|
19 |
Appendix |
|
20 |
About DelveInsight |
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services